{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:26:23Z","timestamp":1765887983230,"version":"3.37.3"},"reference-count":43,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T00:00:00Z","timestamp":1522713600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J of Rheum Dis"],"published-print":{"date-parts":[[2018,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>The onset and progression of ankylosing spondylitis (AS) usually occurs during the life stage when individuals are more likely to be working and receiving an income, but little is known about the effects of interventions that reduce pain and improve the economic circumstances of patients out of the labour force due to AS. This study evaluates the economic benefits of pain reduction among people aged 19\u201364 with AS using adalimumab (Humira<jats:sup>\u00ae<\/jats:sup>) from the patient and governmental perspectives.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We estimated the benefits of adalimumab for reducing pain in people aged 19\u201364 with AS in terms of labor force participation and earnings, and to the Australian Government in terms of income tax revenue and welfare payments using economic simulation. The simulation model integrated data from the Adalimumab Trial Evaluating Long\u2010Term Safety and Efficacy for Ankylosing Spondylitis (ATLAS), the Household Income and Labour Dynamics in Australia (HILDA) Survey \u2013 Wave 10, and Static Incomes Model (STINMOD). All benefits are expressed in 2014 real Australian dollars.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We estimated an additional 131 people aged 19\u201364 with AS (111 males, 20 females) would be in the labour force after using adalimumab for 24 weeks. National benefits consisted of an increase in annual earnings of AU$7.4 million for patients through increased labour force participation, savings of $2 million in annual welfare payments, and an increase of $1.3 million in income tax revenue in 2014 (after 24 weeks).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Adalimumab therapy generates substantial economic benefits in addition to health benefits for individuals, and savings for government.<\/jats:p><\/jats:sec>","DOI":"10.1111\/1756-185x.13277","type":"journal-article","created":{"date-parts":[[2018,4,3]],"date-time":"2018-04-03T07:33:20Z","timestamp":1522740800000},"page":"1106-1113","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["The economic impacts of using adalimumab (Humira<sup>\u00ae<\/sup>) for reducing pain in people with ankylosing spondylitis: A microsimulation study for Australia"],"prefix":"10.1111","volume":"21","author":[{"given":"Deborah","family":"Schofield","sequence":"first","affiliation":[{"name":"Faculty of Pharmacy Charles Perkins Centre The University of Sydney New South Wales Australia"},{"name":"Murdoch Childrens Research Institute Royal Children's Hospital Melbourne Victoria Australia"},{"name":"Garvan Institute of Medical Research Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupendra","family":"Shrestha","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Charles Perkins Centre The University of Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0163-3665","authenticated-orcid":false,"given":"Michelle","family":"Cunich","sequence":"additional","affiliation":[{"name":"Faculty of Pharmacy Charles Perkins Centre The University of Sydney New South Wales Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2018,4,3]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60635-7"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-002-0237-4"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199801)41:1<58::AID-ART8>3.0.CO;2-G"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.019224"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1150-5"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.4.353"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.5.429"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.61.8.693"},{"key":"e_1_2_8_10_1","first-page":"1056","article-title":"Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review","volume":"28","author":"Boonen A","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.60.11.1033"},{"key":"e_1_2_8_12_1","first-page":"315","article-title":"Risk factors for work disability in patients with ankylosing spondylitis","volume":"28","author":"Ward MM","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_13_1","unstructured":"Spondylitis Association of America(2013)Medications used to treat ankylosing spondylitis and related diseases 2013. [cited 7 September.] Available from URL:http:\/\/www.spondylitis.org\/about\/medications.aspx"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar3178"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2011.151563"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21913"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-199206000-00002"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22887"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"e_1_2_8_20_1","first-page":"1346","article-title":"Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long\u2010term safety and efficacy for ankylosing spondylitis (ATLAS)","volume":"35","author":"Revicki DA","year":"2008","journal-title":"J Rheumatol"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087270"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/ar2790"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kem031"},{"key":"e_1_2_8_24_1","unstructured":"The Pharmaceutical Benefits Scheme(2007)Public summary document for Adalimumab: Australian Government Department of Health. [cited 7 September 2016.] Available from URL:http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/2006-11\/pbac-psdadalimumab-nov06"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.00132"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2458-11-418"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.090242"},{"volume-title":"HILDA User Manual \u2010 Release 11","year":"2012","author":"Summerfield M","key":"e_1_2_8_28_1"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwh090"},{"volume-title":"An Introduction to STINMOD: A Static Microsimulation Model","year":"1994","author":"Lambert S","key":"e_1_2_8_30_1"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1571-0386(06)16028-7"},{"key":"e_1_2_8_32_1","unstructured":"Australian Bureau of Statistics(2010)Catalogue Number 6302.0 \u2010 Average Weekly Earnings Australia Aug 2009 Canberra: Australian Bureau of Statistics. [cited 1 February 2017.] Available from URL:http:\/\/www.abs.gov.au\/AUSSTATS\/abs@.nsf\/allprimarymainfeatures\/1EF944D203A728C4CA2576D400124315?opendocument"},{"key":"e_1_2_8_33_1","unstructured":"Australian Government(2014)Guide to Social Security Law Version 1.207 \u2010 Released 19 September 2014. [cited 7 September 2016.] Available from URL:http:\/\/guides.dss.gov.au\/guide-social-security-law\/5\/2\/2\/05"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.11197"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21330"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-005-1150-5"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199908)12:4<247::AID-ART3>3.0.CO;2-H"},{"key":"e_1_2_8_38_1","first-page":"721","article-title":"Employment across chronic inflammatory rheumatic diseases and comparison with the general population","volume":"32","author":"Mau W","year":"2005","journal-title":"J Rheumatol"},{"key":"e_1_2_8_39_1","first-page":"613","article-title":"Disability and handicap in rheumatoid arthritis and ankylosing spondylitis \u2013 results from the German rheumatological database. German Collaborative Arthritis Centers","volume":"27","author":"Zink A","year":"2000","journal-title":"J Rheumatol"},{"key":"e_1_2_8_40_1","first-page":"1056","article-title":"Work status and its determinants among patients with ankylosing spondylitis. A systematic literature review","volume":"28","author":"Boonen A","year":"2001","journal-title":"J Rheumatol"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(200110)45:5<424::AID-ART361>3.0.CO;2-7"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780330712"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2001.tb143675.x"},{"volume-title":"Australia's Health 2014","year":"2014","author":"Australian Institute of Health and Welfare","key":"e_1_2_8_44_1"}],"container-title":["International Journal of Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2F1756-185X.13277","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/1756-185X.13277","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,23]],"date-time":"2023-09-23T23:13:07Z","timestamp":1695510787000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/1756-185X.13277"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,3]]},"references-count":43,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["10.1111\/1756-185X.13277"],"URL":"https:\/\/doi.org\/10.1111\/1756-185x.13277","archive":["Portico"],"relation":{},"ISSN":["1756-1841","1756-185X"],"issn-type":[{"type":"print","value":"1756-1841"},{"type":"electronic","value":"1756-185X"}],"subject":[],"published":{"date-parts":[[2018,4,3]]},"assertion":[{"value":"2018-04-03","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}